Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 4, 2004, Pages 546-552

  Peters, Ulrike ^a   Hayes, Richard B ^a   Chatterjee, Nilanjan ^a   Shao, Wen ^b   Schoen, Robert E ^c   Pinsky, Paul ^a   Hollis, Bruce W ^d   McGlynn, Katherine A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM; SEX DIFFERENCE; SIGMOIDOSCOPY; VITAMIN BLOOD LEVEL;

ADENOMA; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RANDOM ALLOCATION; RECEPTORS, CALCITRIOL; RISK FACTORS; SEX FACTORS; UNITED STATES; VITAMIN D;

EID: 2942612192     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Peters U, McGlynn KA, Chatterjee N, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers & Prev, 2001;10:1267-74.
2. Levine AJ, Harper JM, Ervin CM, et al. Serum 25-hydroxyvitamin D, dietary calcium intake, and distal colorectal adenoma risk. Nutr Cancer, 2001;39:35-41.
3. Platz EA, Hankinson SE, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers & Prev, 2000;9:1059-65.
4. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet, 1989;2:1176-8.
5. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol, 1995;142:608-11.
6. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes & Control, 1997;8:615-25.
7. Marcinkowska E. A run for a membrane vitamin D receptor. Biol Signals Recept, 2001;10:341-9.
8. Norman AW, Bishop JE, Bula CM, et al. Molecular tools for study of genomic and rapid signal transduction responses initiated by 1 α,25(OH)(2)-vitamin D(3). Steroids, 2002;67:457-66.
9. Kim HS, Newcomb PA, Ulrich CM, et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers & Prev, 2001;10:869-74.
10. Beelman CA, Parker R. Degradation of mRNA in eukaryotes. Cell, 1995;81:179-83.
11. Slattery ML, Yakumo K, Hoffman M, Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes & Control, 2001;12:359-64.
12. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature, 1994;367:284-7.
13. Durrin LK, Haile RW, Ingles SA, Coetzee GA. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta, 1999;1453:311-20.
14. Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int, 1986;39:139-44.
15. Aarskog D, Aksnes L, Markestad T, Rodland O. Effect of estrogen on vitamin D metabolism in tall girls. J Clin Endocrinol Metab, 1983;57:1155-8.
16. Harris SS, Dawson-Hughes B. The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr, 1998;17:282-4.
17. Landin-Wilhelmsen K, Wilhelmsen L, Wilske J, et al. Sunlight increases serum 25(OH) vitamin D concentration whereas 1,25(OH) 2D3 is unaffected. Results from a general population study in Goteborg, Sweden (The WHO MONICA Project). Eur J Clin Nutr, 1995;49:400-7.
18. Sowers MR, Wallace RB, Hollis BW, Lemke JH. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr, 1986;43:621-8.
19. Gallagher JC, Riggs BL, DeLuca HF. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab, 1980;51:1359-64.
20. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr, 2002;76:187-92.
21. Heaney RP, Barger-Lux MJ, Dowell MS, Chen TC, Holick MF. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab, 1997;82:4111-6.
22. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002;288:321-33.
23. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes & Control, 2003;14:75-84.
24. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med, 1999;340:101-7.
25. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials, 2000;21:251S-72S.
26. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials, 2000;21:349S-55S.
27. Hollis BW. Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol, 1997;282:174-86.
28. Hernández JL, Weir BS. A disequilibrium coefficient approach to Hardy-Weinberg testing. Biometrics, 1989;45:53-70.
29. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Accessed May 2003. Available from: http://www3.cancer.gov/prevention/plco/DQX.pdf.
30. Subar AF, Midthune D, Kulldorff M, et al. Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol, 2000;152:279-86.
31. Tippett KS, Cypel YS. Design and operation: the continuing survey of food intakes by individuals and the diet and health knowledge survey, 1994-96. In: Continuing survey of food intakes by individuals 1994-96. Nationwide Food Surveys Rep. No. 96-1. U.S. Department of Agriculture, Agricultural Research Service; 1997.
32. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr, 1999;69:842-56.
33. Thomas CL. Taber's cyclopedic medical dictionary. Philadelphia: F.A. Davis Co; 1989.
34. Dusso A, Brown A, Slatopolsky E. Extrarenal production of calcitriol. Semin Nephrol, 1994;14:144-55.
35. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-Hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet, 2001;357:1673-4.
36. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 α-hydroxylase. J Clin Endocrinol Metab, 2001;86:888-94.
37. Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers & Prev, 2002;11:113-9.
38. Cross HS, Bareis P, Hofer H, et al. 25-Hydroxyvitamin D(3)-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids, 2001;66:287-92.
39. 125I-labeled tracer. Clin Chem, 1993;39:529-33.
40. Fraser DR. Regulation of the metabolism of vitamin D. Physiol Rev, 1980;60:551-613.
41. Stern PH, Taylor AB, Bell NH, Epstein S. Demonstration that circulating 1 α, 25-dihydroxyvitamin D is loosely regulated in normal children. J Clin Invest, 1981;68:1374-7.
42. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr, 1990;120 Suppl 11:1464-9.
43. Hollis BW. Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. Calcif Tissue Int, 1996;58:4-5.
44. ten Bolscher M, de Valk-de Roo GW, Barto R, van der Vijgh WJ, Neugut AI. Oestrogen has no short-term effect on intestinal strontium absorption in healthy postmenopausal women. Clin Endocrinol (Oxf), 2003;50:387-92.
45. van Hoof HJ, de Sevaux RG, van Baelen H, et al. Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. Eur J Endocrinol, 2001;144:391-6.
46. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res, 1999;11:255-64.
47. Boyapati SM, Bostick RM, McGlynn KA. Vitamin D intake, vitamin D receptor BsmI polymorphisms, and risk for incident sporadic colorectal adenoma [abstract]. 92nd AACR Annual Meeting; March 24-28, 2001.
48. Ingles SA, Wang J, Coetzee GA, Lee ER, Frankl HD, Haile RW. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes & Control, 2001;12:607-14.